(0.14%) 5 138.50 points
(0.08%) 38 472 points
(0.22%) 17 886 points
(-0.27%) $83.62
(1.72%) $1.956
(0.10%) $2 349.60
(0.41%) $27.65
(1.45%) $935.45
(-0.07%) $0.934
(-0.17%) $11.01
(-0.18%) $0.799
(1.29%) $93.06
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 11.09%
Live Chart Being Loaded With Signals
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology...
Stats | |
---|---|
今日成交量 | 2.07M |
平均成交量 | 2.85M |
市值 | 3.18B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $0.740 ) 2024-05-02 |
Last Dividend | $1.000 ( 2010-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.38 |
ATR14 | $0.00800 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Paulson John | Buy | 5 890 | Common Shares, No Par Value |
2024-03-29 | Icahn Brett | Buy | 3 122 | Common Shares, No Par Value |
2024-03-29 | Robertson Russel C | Buy | 2 945 | Common Shares, No Par Value |
2024-03-29 | Wechsler Amy B | Buy | 647 | Common Shares, No Par Value |
2024-02-29 | Barresi John S | Buy | 39 126 | Common Shares, No Par Value |
INSIDER POWER |
---|
67.94 |
Last 100 transactions |
Buy: 2 132 507 | Sell: 336 154 |
音量 相关性
Bausch Health Companies 相关性 - 货币/商品
Bausch Health Companies 财务报表
Annual | 2023 |
营收: | $8.76B |
毛利润: | $6.20B (70.78 %) |
EPS: | $-1.620 |
FY | 2023 |
营收: | $8.76B |
毛利润: | $6.20B (70.78 %) |
EPS: | $-1.620 |
FY | 2022 |
营收: | $8.12B |
毛利润: | $5.76B (70.90 %) |
EPS: | $-0.590 |
FY | 2021 |
营收: | $8.43B |
毛利润: | $6.04B (71.61 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Bausch Health Companies Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.500 | 2005-11-28 |
Last Dividend | $1.000 | 2010-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2010-12-22 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | $6.43 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.06 | -- |
Div. Sustainability Score | 6.11 | |
Div.Growth Potential Score | 2.84 | |
Div. Directional Score | 4.48 | -- |
Year | Amount | Yield |
---|---|---|
2005 | $0.500 | 3.07% |
2006 | $0.500 | 2.01% |
2007 | $2.00 | 9.47% |
2008 | $1.500 | 11.20% |
2009 | $0.645 | 6.68% |
2010 | $1.280 | 8.72% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0190 | 1.500 | -0.379 | -0.569 | [0 - 0.5] |
returnOnAssetsTTM | -0.00607 | 1.200 | -0.202 | -0.243 | [0 - 0.3] |
returnOnEquityTTM | 0.171 | 1.500 | 9.21 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.301 | 0.800 | 8.50 | 6.80 | [1 - 3] |
quickRatioTTM | 0.685 | 0.800 | -0.679 | -0.543 | [0.8 - 2.5] |
cashRatioTTM | 0.220 | 1.500 | 9.89 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.819 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -0.725 | 1.000 | -1.380 | -1.380 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.00 | 2.00 | 9.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.23 | 2.00 | 8.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | -21.91 | -1.500 | -10.00 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.995 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.110 | 1.000 | 9.80 | 9.80 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0489 | 1.000 | -0.839 | -0.839 | [0.2 - 2] |
assetTurnoverTTM | 0.320 | 0.800 | -1.199 | -0.959 | [0.5 - 2] |
Total Score | 6.11 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -19.16 | 1.000 | -2.04 | 0 | [1 - 100] |
returnOnEquityTTM | 0.171 | 2.50 | 9.49 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.23 | 2.00 | 9.26 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.00 | 2.00 | 9.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.390 | 1.500 | -5.93 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.125 | 1.000 | 9.37 | 0 | [0.1 - 0.5] |
Total Score | 2.84 |
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。